Nuevolution signs cross-licensing deal with GSK
This article was originally published in Scrip
Executive Summary
Nuevolution has agreed a global cross-licensing agreement with GlaxoSmithKline relating to a number of patented technologies developed by Nuevolution and Praecis Pharmaceuticals, which was acquired by GSK in 2007.